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http://dxObjective: Percutaneous transcatheter aortic valve replacement was introduced in 2002, but its effectiveness
remained to be assessed.
Methods: A prospective, randomized trial (the Placement of Aortic Transcatheter Valves, or PARTNER) was
designed with 2 arms: PARTNER A (n ¼ 699) for high-risk surgical patients (Society of Thoracic Surgeons
score>10%, surgeon assessed risk of mortality>15%) and PARTNER B (n ¼ 358, patients inoperable by
assessment of 2 surgeons). PARTNER A patients were divided into femoral artery access transcatheter aortic
valve replacement or none (n¼ 207), and then randomized to open aortic valve replacement (n¼ 351) or device
(n ¼ 348). Inclusion criteria included valve area<0.8 cm2, gradient>40 mm Hg or peak>64 mm Hg, and sur-
vival>1 year. The end point of the study was 1-year mortality.
Results: Thirty-day mortality for PARTNER Awas 3.4% for transcatheter aortic valve replacement and 6.5%
for aortic valve replacement; 1-year mortality was 24.2% and 26.8%, respectively (P¼ .001 for noninferiority).
The respective prevalence of stroke was 3.8% and 2.1% (P ¼ .2), although for all neurologic events, the
difference between transcatheter aortic valve replacement and aortic valve replacement was significant (P ¼
.04), including 4.6% for femoral artery access transcatheter aortic valve replacement versus 1.4% for open
aortic valve replacement (P ¼ .05). For PARTNER B—transcatheter aortic valve replacement versus medical
treatment—30-day mortality was 5.0% versus 2.8% (P ¼ .41), and at 1 year, mortality was 30.7% versus
50.7% (P<.001), respectively. Hospitalization cost of transcatheter aortic valve replacement for PARTNER
B was $78,542, or $50,200 per year of life gained. Analysis of PARTNER A strokes showed that hazard with
transcatheter aortic valve replacement peaked early, but thereafter remained constant in relation to aortic valve
replacement. Two-year PARTNER A data showed paravalvular regurgitation was associated with increased
mortality, even when mild (P<.001). Continued access to transapical transcatheter aortic valve replacement
(n ¼ 853) showed a mortality of 8.2% and decline in strokes to 2.0%. Of the 1801 Cleveland Clinic patients
reviewed to December 2010, 214 (12%) underwent transcatheter aortic valve replacement with a mortality
of 1%; in 2011, 105 underwent transcatheter aortic valve replacement: 34 transapical aortic valve replacement,
with no deaths, and 71 femoral artery access aortic valve replacement with 1 death.
Conclusions: The PARTNER A and B trials showed that survival has been remarkably good, but stroke and
perivalvular leakage require further device development. (J Thorac Cardiovasc Surg 2013;145:S11-6)H.R. Andersen first obtained a patent for an intra-aortic valve
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The Journal of Thoracic and Carpersisted with developing the technology using a femoral
transvenous approach.1–6 A transapical (TA) transcatheter
aortic valve replacement (TAVR) approach was then
developed, followed by a transarterial femoral (TF)
approach and, more recently, transaortic and transaxillary
approaches. Two initial feasibility trials were performed in
the United States for both TA-TAVR and TF-TAVR.1-23
The PARTNER trial (Placement of Aortic Transcatheter
Valves) was designed as a multicenter randomized trial
comparing open standard aortic valve replacement (AVR)
with TAVR in high-risk patients, and also TAVR versus
standard medical treatment.1,2,5,6 In addition, cost
analysis, 2-year data analysis, and stroke analysis have
been done, as well as analysis of continued access for
TA-TAVR.1,2,4,21
METHODS
A total of 3105 patients were presented to aWeb-based review panel for
potential inclusion in the trial (Figure 1). Ultimately, 12% were enrolled;
however, the number of patients reviewed at sites but not presented wasdiovascular Surgery c Volume 145, Number 3S S11
Panel 1 Svensson et alS1Abbreviations and Acronyms
AVR ¼ aortic valve replacement
BMI ¼ body mass index
COPD ¼ chronic obstructive pulmonary
disease
FDA ¼ Food and Drug Administration
PARTNER ¼ Placement of Aortic
Transcatheter Valves
STS ¼ Society of Thoracic Surgeons
TA ¼ transapical
TAVR ¼ transcatheter aortic valve
replacement
TF ¼ transarterial femoral2 The Jourconsiderably higher. For example, as of December 2010 at Cleveland
Clinic, we had reviewed 1801 patients who were considered potential trial
participants. If patients presented for potential enrollment but clearly were
not candidates based on inclusion and exclusion criteria, they were then
reviewed for surgery, balloon dilatation, or medical treatment. Hence, of
the 1801 patients reviewed formally and discussed at our weekly Tuesday
morning meeting, 193 went on to surgery and 214 went on to enrollment
into TAVR studies. During the same period, the number of patients who
underwent open AVR was noted.
Briefly, PARTNER A patients were required to be high risk for conven-
tional open valve surgery.1,5 This was determined by a minimal Society of
Thoracic Surgeons (STS) score of 10% for death, and the surgeons’
assessment of the risk as>15%. In addition, patients were required to
have symptomatic aortic valve stenosis with an area <0.8 cm2, and
gradients either> a mean of 40 mm Hg or a peak of 64 mm Hg, the
latter equivalent to a velocity of 4 m/second. The list of exclusions
included recent myocardial infarction, stroke, infections, creatinine level
>3.0 mg/dL, and patients not likely to survive a year. For PARTNER
B,2,6 patients approved for the study were required to have 2 cardiac
surgeons agree that they were inoperable based on a combined risk of
death and irreversible severe morbidity>50%.
Data on hospital costs were also collected. After completion of the trial,
patients could be enrolled in continued access to TAVR in PARTNER A
and PARTNER B. Furthermore, after 1 year, surviving patients were
allowed to cross over in PARTNER B. PARTNER B patients listed as
having died from unknown causes underwent careful review to determine
cause of death.
The trial was designed by members of the PARTNER executive com-
mittee and the sponsor (Edwards Lifesciences), with additional input and
approval from the U.S. Food and Drug Administration (FDA). In June
2006, the proposal for a randomized trial with 2 arms for either inoperable
or high-risk surgical patients was proposed by 3 of us (L.G.S., E.H.B., and
B.W.L.) and other surgeons, with the high-risk surgical patients random-
ized to open AVR, TF-TAVR, or TA-TAVR. The final trial was designed
based on extensive discussion, and TA-TAVR was dropped from random-
ization in patients with femoral access. The executive committee and prin-
cipal investigators had full access to all the data after the database was
locked. An independent clinical events committee arbitrated events and
complications. For PARTNER B deaths and neurologic events in
PARTNER A, clinical events committee records were reviewed in detail.
An independent echocardiography core laboratory assessed echocardio-
graphic outcomes.
The device used for the study consisted of a stainless steel tubular mesh
stent with internal bovine pericardial leaflets (Edwards LifeSciences’nal of Thoracic and Cardiovascular SurgSapien valve). The device was loaded onto an inflatable balloon within
a loader. A balloon dilatation was performed first and then, when the device
was positioned correctly, the balloonwas inflated during rapid pacing of the
heart, usually at 180 to 200 beats per minute. Transesophageal echocardi-
ography was used to check correct position, supplemented as needed by
root aortography. Technical steps for device insertion have been described
previously. The study end points were 1-year survival, with documentation
of complications and their effects on 1-year survival.
For PARTNER A, the trial was designed for noninferiority of TAVR
versus open AVR and, furthermore, the TF-TAVR group assignment was
powered to compare TF-TAVR noninferiority with open surgery. This
was not done for TA-TAVR. Based on this design, 650 patients were
required for PARTNER Awith at least 85% power to show noninferiority
of TAVR assuming a 1-year mortality of 29% for TAVR and 32% for AVR.
Similarly, 450 patients were required for TF-TAVR power. For PARTNER
B, the trial was for superiority of TF-TAVR versus medical treatment in the
control arm. To achieve 85% power to show superiority, 350 patients were
required, assuming 37.5%mortality in the control subjects and 25% in the
TAVR patients. In the case of PARTNER B, to analyze the nonprimary end
point of both death and repeat hospitalization, the Finkelstein-Schoenfeld
nonparametric method was used.20 To do this, all patients had multiple
pairwise comparisons performed, first with respect to time to death and
to repeat hospitalization, if the latter occurred.RESULTS
For PARTNERA, 351 patients were assigned to AVR and
348 to TAVR, of whom 244 were TF-TAVR and 104 TA-
TAVR.1,5 Variables were mostly well balanced between
AVR and TAVR, and the mean STS score was 11.8%.
Actual AVR mortality was 8%, a 0.68 observed-to-
expected ratio compared with STS score. Patients in the
non-TF-TAVR were considered for TA-TAVR; however,
they had more previous coronary artery bypasses, percuta-
neous coronary interventions, cerebrovascular disease, pre-
vious carotid endarterectomies, peripheral arterial disease,
porcelain aortas, radiation heart disease, and severe aortic
valve stenosis, the latter a risk factor for neurologic events.
Forty-two patients did not undergo treatment as assigned.
For TAVR, 3 patients died during the procedure, 16 had
the procedure aborted or converted to open operation, 7
had multiple valves inserted (3 patients died), and another
7 were aborted because of valve embolization, for a total
of 33 procedure failures (9.5%). Thirty-daymortality for in-
tention to treat for was 3.4% for TAVR and 6.5% for AVR
(P ¼ .07); for TF-TAVR, mortality was 3.3% versus 6.2%
with AVR (P ¼ .13). For TA-TAVR, 30-day mortality was
3.8% and control AVR was 7.0% (P ¼ .32, intention to
treat). At 1 year, mortality was 24.2% for TAVR and
26.8% for AVR, with no significant difference, meeting
noninferiority. Prevalence of neurologic events for TAVR
versusAVRat 30 dayswas 5.5% versus 2.4% (P¼ .04);ma-
jor strokes was 3.8% versus 2.1% (P ¼ .2). For all neuro-
logic events, TF-TAVR versus open AVR was 4.6% versus
1.4% (P ¼ .05). Subgroup analysis showed that women
fared better with TAVR and patients undergoing reopera-
tions fared better with open AVR, contrary to expectations,
and not fully explained.Other events includedmorevascularery c March 2013
FIGURE 1. PARTNER cohort diagram. PARTNER, Placement of Aortic Transcatheter Valves; AVR, aortic valve replacement; TAVR, transcatheter aortic
valve replacement; TF, transarterial femoral; TA, transapical.
Svensson et al Panel 1complicationswithTAVR, less bleeding, andmoremoderate
or severe paravalvular regurgitation (10.5% at 6 months).
For PARTNER B,2,6 358 patients were enrolled, and
baseline variables were mostly well balanced. The
average STS score was 11.6%, but many patients who
were deemed inoperable would not have had a high
score—for example, with porcelain aortas (15.1% of
patients), chest deformity or radiation (13.1%), severe
chronic obstructive pulmonary disease (COPD, 23.5%),
or severe frailty (23.1%)—because those comorbidities
are not captured completely by the STS scoring.
Of the 179 TAVR patients, 6 did not undergo a successful
procedure (2 for failed access, 2 for too large an annulus), 2
died during the procedure, 1 had embolization, 2 underwent
multiple valve implantations, and 11 died within 30 days
(11/173, 6.4%). None had open surgery. Thus, 9 patients
(6%) did not have a successful valve insertion. Of note,
63.7% in the control group underwent balloon valvulo-
plasty within 30 days (63.7%) and an additional 20%
underwent balloon valvuloplasty after 30 days. A total of
6.7% had AVR; 2.8%, left ventricular apex to descending
aorta conduit; and 2.2% underwent TAVR outside the
United States. At 30 days after randomization, TAVR mor-
tality was 5.0% and control was 2.8% (P ¼ .61), and at 1
year the mortality was 30.7% for TAVR and 50.7% for
control.The Journal of Thoracic and CarFor the primary end point—death or rehospitalization—
by Finkelstein-Schoenfeld analysis, TAVR was also supe-
rior to control (P< .001). Major strokes at 30 days were
5.0% versus 1.1% (P ¼ .06), and at 1 year, 7.8% versus
3.9% (P ¼ .18). Moderate to severe paravalvular aortic re-
gurgitation was present in 11.8% at 30 days and 10.5% at 1
year. Moderate or severe central regurgitation was present
in 1.3% at 30 days and 4.2% at 1 year. Subgroup analysis
showed patients with severe mitral valve regurgitation and
larger body size (body mass index [BMI] >25 kg/m2)
tended to benefit more from TAVR. Detailed analysis of pa-
tients with unknown causes of death showed most had died
in nursing homes or hospice from multiple sources of organ
failure, failure to thrive, and general old age and frailty,
without a specific cause. Multiple variable analyses showed
that, for TAVR, the best independent predictors were STS
score and BMI. After TAVR, it is of interest that the effect
of differences in the EuroSCORE, ejection fraction and age
was largely negated and had no influence on late outcomes.
Two-year data analysis of PARTNER A1 and B2
confirmed the 2 previous reports, but also added further
information on late outcomes concerning stroke and para-
valvular leaks. In particular, the update of PARTNER A
showed an additional 32 TAVR deaths and 25 AVR deaths,
with no difference at 2 years (33.9% and 35%, respectively,
P ¼ .78).diovascular Surgery c Volume 145, Number 3S S13
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stroke, endocarditis, hemolysis, and ongoing heart failure.
Stroke or transient ischemic attack occurred in 11.2%
with TAVR versus 6.5% with AVR (P ¼ .05) at 2 years,
but after the early hazard, this did not change. Of note, there
were no repeat TAVRs between 1 and 2 years, and the
prevalence of endocarditis was similar between the groups
(1.5% and 1.0%, P ¼ .61). No hemolysis was documented
for TAVR, and rehospitalization and New York Heart Asso-
ciation classes were similar. Of interest, the multivariable
late predictors for deaths (TAVR and AVR) were BMI
(P< .01), liver disease (P ¼ .006), STS score (P ¼ .02),
and moderate or severe mitral valve regurgitation (P ¼
.04); a higher mean gradient was protective (P ¼ .02). For
TAVR alone, the predictors were BMI (P<.001), preoper-
ative creatinine level (P ¼ .04), and prior vascular surgery
or stent (P ¼ .05); high mean gradients were protective
(P ¼ .003). For AVR, the predictors were STS score (P ¼
.004), liver disease (P¼ .02), and moderate or severe mitral
valve regurgitation (P ¼ .006), and prior coronary artery
bypass grafting was protective (P ¼ .002).
Of particular note was the influence of paravalvular re-
gurgitation.1 It was moderate in 7.0% and severe in 1.9%
at 1 year, and at 2 years, the respective values were 6.9%
and 0.9% (P<.001 for both intervals), and it tended to im-
prove over time for TAVR. Paravalvular or total aortic
regurgitation after TAVR was associated with worse sur-
vival (P<.001), and even mild regurgitation increased mor-
tality. Given the strong influence of mild regurgitation and
the difficulty in grading paravalvular regurgitation after
TAVR, it is possible that the label ‘‘mild’’ underestimated
regurgitation that was likely more severe.
For PARTNER B,2 the noteworthy findings at 2 years
were a 68%mortality with conventional medical treatment,
43.3% for TAVR (P<.005), and crossover after 1 year did
not affect results; however, 1-year mortality after TAVR
crossover was 10% compared with 21% for those who
did not receive TAVR and cross over. Of the 82.3% who
had balloon valvuloplasty, there appeared to be an initial
6-month benefit, but a time-dependent covariable analysis
failed to show any benefit. The multivariable predictors of
poor late survival were lower BMI (P ¼ .005), prior stroke
(P¼ .01), and COPD and oxygen (P¼ .03). The STS score
was a predictor for survival after TAVR (P ¼ .01). Of note,
for patients with an STS score of<5%, after TAVR—usu-
ally for radiation heart disease or porcelain aorta—2-year
survival was about 80% (P¼ .04), and this group benefited
the most. Prevalence of strokes for TAVR was higher than
after medical treatment at both 1 and 2 years. After 30
days and up to 2 years, 9 strokes occurred with TAVR and
5 with medical treatment, although the influence of balloon
valvuloplasty was not examined.
The detailed analysis of stroke after TAVR or AVR in
PARTNER A showed that 51% of strokes were procedureS14 The Journal of Thoracic and Cardiovascular Surgrelated, and 38% occurred within 2 days: 43% of patients
ultimately died.3 Analysis by procedure showed that for
neurologic events (1.4% at 30 days), open AVR had the
lowest risk followed by TF-TAVR (4.6% at 30 days; P ¼
.05), then group non-TF, with no difference between TA-
TAVR and open AVR. Overall, for both TAVR and open
AVR, the early multivariable predictors of neurologic
events were TAVR versus open AVR, preprocedure cerebro-
vascular disease, and smaller indexed native aortic valve
area. The late hazard phase predictors were TAVR versus
open AVR, higher NewYork Heart Association class, stroke
within 6 to 12 months, non-TF-TAVR group, with less risk
with previous percutaneous coronary intervention, and
COPD.
Cost analysis for PARTNER B showed a mean cost of
$78,542 and a median length of hospital stay of 10.1
days, 8.6 days postprocedural.4 One-year postprocedure
cost was $18,074 and, based on an estimated 3.1-year sur-
vival, total life cost after the trial during the first year was
$43,664, for a grand total of $140,280 per patient, which
turns out to be $50,212 per life-year gained. The cost of
the valve for the calculations was $30,000 per device, but
the current cost is $32,500 per device. For quality-
adjusted survival gain, the cost was $61,889 per year.
Health-related quality of life analysis in PARTNER B
patients showed that Kansas City Cardiomyopathy Ques-
tionnaire score improvement was better at 30 days with
TAVR than control (P<.001), with an even greater benefit
at 6 months and 12 months (P<.001).21 Physical and men-
tal scores (SF-12 [Short Form-12] General Health Survey)
were also better (P<.001) with TAVR than in nonoperated
controls.
The Center forMedicare andMedicaid Services conduct-
ed a detailed review of the PARTNER trial data based on the
reported results, and also there has been FDA analysis and
assessment by the Belgian and British (NICE) Health
Authorities. The Center for Medicare and Medicaid Ser-
vices also recommended draft requirements for a program
to be reimbursed for carrying out TAVR. For previous
PARTNER TAVR research sites, the requirements were
>50 AVRs per year, 10 with an STS score>6,>2 cardiac
surgeons, >400 catheterizations/150 percutaneous inter-
ventions per year, and >15 endovascular or thoracic
endovascular aneurysm repair procedures per year. For
continued reimbursement, requirements were ongoing
involvement in trials or postapproval studies,>30 TAVR
procedures and>20/year, 30-day mortality<15%, neuro-
logic events<15%, 90% follow-up, and>60% 1-year sur-
vival for inoperable patients. Surgeons are also required to
be qualified, to have performed>100 AVRs, including>10
high risk or>25/year, and>20 in the year prior to approval.
Under the requirements of National Coverage Determina-
tion payments for Medicare Parts A or B, payments
may not occur for procedures that are not reasonable orery c March 2013
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tion. The Center for Medicare and Medicaid Services asked
2 questions: (1) Is the evidence adequate to conclude that
TAVR improves health outcomes of Medicare beneficiaries
with severe symptomatic aortic stenosis who are not candi-
dates for surgical AVR [PARTNER B]? The Center for
Medicare and Medicaid Services concluded that ‘‘the evi-
dence is not adequate to conclude that TAVR generally
improves health outcomes.’’ TAVR, however, may improve
health outcomes ‘‘in carefully monitored clinical studies
performed by expert multi-disciplinary heart teams’’ and
monitored in the STS/American College of Cardiology
Transcatheter Valve Technology Registry.24 (2) Is the evi-
dence adequate for high surgical risk candidates for AVR
[PARTNER A]? The Center for Medicare and Medicaid
Services determined that ‘‘for the highly selected patients
in Cohort A, TAVR provided no mortality benefit but signif-
icant risk of harms. We believe that Medicare coverage for
this patient population should be restricted only to clinical
trials rather than registries.’’
Results of TA-AVR continued access showed that experi-
ence had grown from an average of 7.4 cases per site in
PARTNER A to 38.4 cases per site. Continued access pa-
tients were older (P ¼ .007), STS score stayed the same,
prior coronary interventions increased to 85.6% (P ¼ .01;
50% coronary artery bypass grafting, 47% percutaneous
coronary intervention [P¼ .002], and 30.5% balloon aortic
valvuloplasty [P¼ .0002]). Thirty-day and 1-year mortality
were 8.2% and 23.6%, versus PARTNER ATA-AVR 8.7%
and 29%, and 7.6% and 25% for AVR. The most marked
improvement was the decline in stroke prevalence to
2.0%, versus 7.0% with TA-AVR and 5.5% with AVR.
Mortality and prevalence of stroke were lower for the newer
sites, indicating the benefit of sharing experience between
sites, and also an improvement in techniques.
Of the 1801 Cleveland Clinic patients reviewed up to De-
cember 2010, 214 (12%) underwent TAVR with a mortality
of 1%; in 2011, 105 underwent TAVR: 34 TA-AVRs with
no deaths and 71 TF-AVRs with 1 death.
DISCUSSION
Remarkably good survival has been achieved with the
new balloon expandable aortic valve devices. There is
a price accompanying the procedure, however22,23—
namely, neurologic events and groin injury—although the
PARTNER trial data (A vs B and TA-TAVR continued ac-
cess) suggest that these risks are diminishing. Indeed, the
newer filter devices will likely reduce the risk of stroke fur-
ther. Furthermore, the newer percutaneous closure devices
and improved femoral artery closure methods have reduced
the risk of bleeding. The transaortic approach also has
a minimal risk of bleeding-related complications.
The extent of use and adoption of these deviceswill clearly
depend on FDA approval for high-risk surgical patients, andThe Journal of Thoracic and Caralso the Center for Medicare and Medicaid Services cover-
age. This will become better clarified during the next few
months. Furthermore, the PARTNER A II trial is evaluating
the device in lower risk patients (STS score>4%) and will
help define the influence of less severe comorbidity on out-
comes. The limitations of the trial are the selective nature
of the patients treated with the device; in our hands, only
12% of patients were enrolled. Nevertheless, rarely in car-
diovascular medicine, and certainly for valve surgery, has
such a well-controlled and funded trial been performed.
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